Eledon Pharmaceuticals, Inc. Common Stock (ELDN) is a publicly traded Healthcare sector company. As of May 21, 2026, ELDN trades at $3.73 with a market cap of $276.33M and a P/E ratio of -7.20. ELDN moved +6.98% today. Year to date, ELDN is +132.73%; over the trailing twelve months it is +25.49%. Its 52-week range spans $1.35 to $5.54. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces ELDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Eledon Unveils BESTOW Data, Phase III Launch Plans and FDA Timeline: Eledon Pharmaceuticals presented updated BESTOW study data for its Tego immunotherapy and outlined plans to initiate a global Phase III trial. Company executives also provided an FDA submission timeline contingent on completion of the pivotal study.
| Metric | Value |
|---|---|
| Price | $3.73 |
| Market Cap | $276.33M |
| P/E Ratio | -7.20 |
| EPS | $-0.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.54 |
| 52-Week Low | $1.35 |
| Volume | 7 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-45.62M |
| Gross Margin | 0.00% |
3 analysts cover ELDN: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.